ReviewTranslational andrology and urology2017
Positron emission tomography (PET) in primary prostate cancer staging and risk assessment.
Review in Translational andrology and urology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 46 citations in OpenAlex.
- Theranostic Potential of a NewPharmaceutics · 2025Article
- Evaluating the prognostic value of radiomics and clinical features in metastatic prostate cancer using [Physical and engineering sciences in medicine · 2025Article
- Automated radiosynthesis and preclinical evaluation of two new PSMA-617 derivatives radiolabelled via [EJNMMI radiopharmacy and chemistry · 2024Article
- Radiotheranostics in advanced prostate cancer: Current and future directions.Prostate cancer and prostatic diseases · 2024Review
- Cost-Effectiveness Modeling of Prostate-Specific Membrane Antigen Positron Emission Tomography with Piflufolastat F 18 for the Initial Diagnosis of Patients with Prostate Cancer in the United States.PharmacoEconomics · 2024Article
- Periprostatic Adipose Tissue: A New Perspective for Diagnosing and Treating Prostate Cancer.Journal of Cancer · 2024Review
- Detecting and Locating the Site of Local Relapse UsingMolecular imaging and biology · 2023Article
- Alteration of Lipid Metabolism in Prostate Cancer: Multifaceted Oncologic Implications.International journal of molecular sciences · 2023Review
- Multiple metabolic pathways fuel the truncated tricarboxylic acid cycle of the prostate to sustain constant citrate production and secretion.Molecular metabolism · 2022Article
- Prostate-specific membrane antigen (PSMA) fusion imaging in prostate cancer: PET-CTThe British journal of radiology · 2022Review
- Metabolic reprogramming as an emerging mechanism of resistance to endocrine therapies in prostate cancer.Cancer drug resistance (Alhambra, Calif.) · 2021Review
- Prognostic Value of CT-Attenuation andJournal of personalized medicine · 2020Article
- Modular Medical Imaging Agents Based on Azide-Alkyne Huisgen Cycloadditions: Synthesis and Pre-Clinical Evaluation ofChemistry (Weinheim an der Bergstrasse, Germany) · 2020Article
- Tumour metabolism and its unique properties in prostate adenocarcinoma.Nature reviews. Urology · 2020Review
- New Frontiers in Molecular Imaging Using Peptide-Based Radiopharmaceuticals for Prostate Cancer.Frontiers in chemistry · 2020Review
- Article
- Exploration of the diagnostic value and molecular mechanism of miR‑1 in prostate cancer: A study based on meta‑analyses and bioinformatics.Molecular medicine reports · 2018Article
- Non-invasive Early Response Monitoring of Nanoparticle-assisted Photothermal Cancer Therapy UsingNanotheranostics · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 3 countries.
Funding
Abstract
Prostate cancer (PCa) is one of the few neoplasms that are not well served by 18F-Fluorodeoxyglucose (FDG) positron emission tomography (PET). As a result, a number of PET tracers have been developed to target particular biological features of PCa. Such agents can be used for diagnosis, staging, identification of biochemical recurrence (BCR) and evaluation of metastatic disease. Here, we focus on primary disease and local staging. To date, magnetic resonance imaging (MRI) has proven superior to PET in the imaging of primary PCa. However, some PET agents have shown remarkable promise in staging high-risk PCa (defined as any combination of a clinical T3, a PSA score >20 ng/mL, or a Gleason score of 8-10), as well as biochemical relapse after definitive therapy and metastatic PCa. PET agents can be divided into those that interrogate tumor metabolism (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.